Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
Crossref DOI link: https://doi.org/10.1007/s40121-022-00660-6
Published Online: 2022-06-24
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yang, Joe http://orcid.org/0000-0002-8158-3003
Naik, Jaesh
Massello, Matthew
Ralph, Lewis
Dillon, Ryan James
Text and Data Mining valid from 2022-06-24
Version of Record valid from 2022-06-24
Article History
First Online: 24 June 2022